longbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesLongbridge ProFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge

REX Peptide ETF

PEPT

28.0991.38% ( +0.382 )
Closed: Nov 13, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsWikiWikiRatingsRatingsCompositionCompositionDividendsDividends

Overview

REX Peptide ETF (PEPT)

Open
27.880
High
28.130
Low
27.520
Prev. Close
27.717
Volume
6.63K
Turnover
184.55K
Avg Price
27.843
Bid/Ask Ratio
0.00%
Amplitude
2.20%
52wk High
29.330
Volume Ratio
0.00
Turnover Ratio
--
52wk Low
25.055
Float Mkt Cap
--
Dividend YieldTTM
--
DividendTTM
--
NAV
--
NAV Date
--
Disc/Prem Rate
--
Total Issued
0.00
Assets
--
Min lot size
1
Currency
USD

News

  • prnewswire · Nov 15, 2026 at 01:00 PM

    Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026

  • PUBT · Nov 15, 2026 at 05:05 PM

    Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial

  • CoinLive · Nov 15, 2026 at 11:43 PM

    Eli Lilly’s Zepbound Helps Adolescents Lose Weight in Study

  • businessinsider · Nov 15, 2026 at 09:17 PM

    Novo Nordisk announces results from two post hoc analyses of phase 3 Redefine 1

  • PUBT · Nov 14, 2026 at 05:01 PM

    Eli Lilly’s EloraTZP delivers up to 23.3% average weight loss in Phase 2 trial

  • rttnews · Nov 14, 2026 at 03:11 AM

    Novo Nordisk Secures EU Approval For FREHEMGO In Haemophilia A

LongbridgeAI
© 2026 Longbridge|Terms of ServicePrivacy Policy